153 related articles for article (PubMed ID: 3501108)
1. Evidence for the presence in sera from chronic myelogenous leukemia patients of an activity that enhances the number of normal bone marrow-derived granulocyte/monocyte committed stem cell colonies.
Rao SG; Kothari V; Nadkarni K; Ahuja H; Advani S
Nouv Rev Fr Hematol (1978); 1987; 29(4):231-6. PubMed ID: 3501108
[TBL] [Abstract][Full Text] [Related]
2. Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients.
Talpaz M; Spitzer G; Hittelman W; Kantarjian H; Gutterman J
Exp Hematol; 1986 Aug; 14(7):668-71. PubMed ID: 3460811
[TBL] [Abstract][Full Text] [Related]
3. Discordant maturation as the primary biological defect in chronic myelogenous leukemia.
Strife A; Lambek C; Wisniewski D; Wachter M; Gulati SC; Clarkson BD
Cancer Res; 1988 Feb; 48(4):1035-41. PubMed ID: 3422181
[TBL] [Abstract][Full Text] [Related]
4. Production of colony-stimulating factor(s) for granulocyte-macrophage and multipotential (granulocyte/erythroid/megakaryocyte/macrophage) hematopoietic progenitor cells (CFU-GEMM) by clonal lines of human IL-2-dependent T-lymphocytes.
Greenberger JS; Krensky AM; Messner H; Burakoff SJ; Wandl U; Sakakeeny MA
Exp Hematol; 1984 Oct; 12(9):720-7. PubMed ID: 6333354
[TBL] [Abstract][Full Text] [Related]
5. G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia.
Lee J; Kim Y; Lim J; Kim M; Han K
Ann Clin Lab Sci; 2008; 38(4):331-7. PubMed ID: 18988925
[TBL] [Abstract][Full Text] [Related]
6. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
7. [Serum factors in chronic myeloid leukemia].
Heilmann E; Eitemöller H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(6):886-900. PubMed ID: 2419218
[TBL] [Abstract][Full Text] [Related]
8. Characterization of lineage-negative blast subpopulations derived from normal and chronic myelogenous leukemia bone marrows and determination of their responsiveness to human c-kit ligand.
Strife A; Perez A; Lambek C; Wisniewski D; Bruno S; Darzynkiewicz Z; Clarkson B
Cancer Res; 1993 Jan; 53(2):401-9. PubMed ID: 7678076
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1.
McCrady CW; Li F; Pettit GR; Grant S
Exp Hematol; 1993 Jul; 21(7):893-900. PubMed ID: 7686503
[TBL] [Abstract][Full Text] [Related]
10. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
Lemoli RM; Gulati SC
Stem Cells; 1993 Sep; 11(5):435-44. PubMed ID: 7694721
[TBL] [Abstract][Full Text] [Related]
11. Special Education.
Kozutsumi H
Oncologist; 1996; 1(1 & 2):116-118. PubMed ID: 10387976
[TBL] [Abstract][Full Text] [Related]
12. Lack of normal CFU-C/suppressor activity in population of alloantigen-stimulated T cells from patients with chronic myelogenous leukemia.
Maekawa T; Sonoda Y; Yokota S; Abe T
Exp Hematol; 1986 May; 14(4):316-23. PubMed ID: 2938981
[TBL] [Abstract][Full Text] [Related]
13. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
Papadakis V; Ferguson KF; Heller G; Kernan NA
Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
Després D; Goldschmitt J; Aulitzky WE; Huber C; Peschel C
Exp Hematol; 1995 Dec; 23(14):1431-8. PubMed ID: 8542928
[TBL] [Abstract][Full Text] [Related]
15. Abnormal regulation of granulopoiesis by bone marrow fibroblasts in leukemia.
Shimizu M; Nagao T; Arimori S
Tokai J Exp Clin Med; 1987 May; 12(2):67-72. PubMed ID: 3482486
[TBL] [Abstract][Full Text] [Related]
16. Effects of S-phase-specific agents on granulocyte-macrophage and erythroid progenitor cells obtained from normal individuals and from patients with chronic myelogenous leukemia.
Kubota K; Preisler HD; Costanzo C
Cancer Res; 1983 Aug; 43(8):3927-31. PubMed ID: 6574819
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in treated patients with chronic myelogenous leukemia in chronic phase.
Balleari E; Bason C; Visani G; Gobbi M; Ottaviani E; Ghio R
Haematologica; 1994; 79(1):7-12. PubMed ID: 15378942
[TBL] [Abstract][Full Text] [Related]
18. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
19. Long-term culture of human bone marrow macrophages: macrophage development is associated with the production of granulomonopoietic enhancing activity (GM-EA).
Wang SY; Castro-Malaspina H; Moore MA
J Immunol; 1985 Aug; 135(2):1186-93. PubMed ID: 3891852
[TBL] [Abstract][Full Text] [Related]
20. Cell culture studies and oncogene expression in juvenile chronic myelogenous leukemia.
Gualtieri RJ; Castleberry RP; Gibbons J; Miller DM; Berkow RL; Parmley RT; Banks J
Exp Hematol; 1988 Aug; 16(7):613-9. PubMed ID: 2968914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
